AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

“Today we are witnessing a renewed wave of pressure through FTAs with developed countries (trying) to incorporate TRIPS-plus provisions, which include patent term extension beyond 20 years, data ...

Russian drugmaker Geropharm has received a compulsory license from the Russian state to produce a generic of Ozempic (semaglutide) developed by Denmark’s Novo Nordisk (NOV: N). As in case of Ozempic, ...

This comes against a backdrop of already booming pharmaceutical exports from European Union (EU) member states to the United States, such as Ireland, which recently witnessed a 450% surge from € ...

A National Bureau of Economic Research study estimates that reducing U.S. pharmaceutical prices by 40% to 50% could lead to a 30% to 60% reduction in research initiatives.